This Biotech Reprogrammes Our Own Cells To Heal The Body – Enlivex Therapeutics (NASDAQ:ENLV)

Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. ENLV was recently a guest on Biedex Markets’s All-Access.

Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis and other indications.

The company’s therapy, Allocetra^TM, is being tested as a cure for sepsis, one of the biggest unmet needs in healthcare. Sepsis is the third leading cause of death in hospitals today.

Watch the full interview here:

Featured photo by Pawel Czerwinski on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.